Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01626183
First received: June 20, 2012
Last updated: May 13, 2016
Last verified: May 2016

June 20, 2012
May 13, 2016
May 2012
May 2016   (final data collection date for primary outcome measure)
Identification and characterization of IncRNA of pediatric T-cell acute lymphoblastic leukemia [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01626183 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia
Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer

PURPOSE: This laboratory study is looking into RNA in samples from younger patients with T-cell (T) acute lymphoblastic leukemia (ALL).

OBJECTIVES:

  • Characterization of the transcriptomic landscape in diagnosis and relapse of T-cell acute lymphoblastic leukemia (ALL) and the direct comparison with corresponding physiological samples (human thymus).
  • Perform high-throughput transcriptome ribonucleic acid (RNA) sequencing using matched diagnostic T-precursor pediatric ALL samples (peripheral blood or bone marrow).

OUTLINE: Archived peripheral blood and bone marrow samples are analyzed for long non-coding RNA (IncRNA) expression and sequencing.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
RNA
Non-Probability Sample
pediatric patients with diagnosed or relapsed T-ALL
Leukemia
  • Genetic: RNA analysis
  • Genetic: proteomic profiling
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
May 2016
May 2016   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Peripheral blood and bone marrow samples from pediatric patients with diagnosed and relapsed T-ALL

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01626183
AALL12B8, COG-AALL12B8, CDR0000735509, NCI-2012-01980
No
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Iannis Aifantis, PhD New York University School of Medicine
Children's Oncology Group
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP